Русский
Association of fibrosis with nutritional status in case of non-alcoholic fatty liver disease
DOI: https://dx.doi.org/10.18565/therapy.2024.5.49-58
Znakharenko E.A., Gerasimenko O.N., Maksimov V.N., Gorbunova A.M.
1) Novosibirsk State Medical University of the Ministry of Healthcare of Russia; 2) Novosibirsk Regional Clinical Hospital of War Veterans No. 3; 3) Research Institute of Therapy and Preventive Medicine – a branch of Institute of Cytology and Genetics of Siberian branch of the Russian Academy of Sciences, Novosibirsk
The aim: to estimate some potential risk factors for fibrosis formation in NAFLD patients with different body mass index (BMI).
Material and methods. The study took place on the basis of Novosibirsk Regional Clinical Hospital of War Veterans No. 3 and Research Institute of Therapy and Preventive Medicine – a branch of Institute of Cytology and Genetics of Siberian branch of the Russian Academy of Sciences and included 349 patients: 113 of them with NAFLD without obesity according to BMI, 122 patients with NAFLD with obesity according to BMI and 114 apparently healthy persons. Nutritional status, levels of biochemical and hormonal indexes, as well as the degree of fibrosis in patients with NAFLD were assessed.
Results. As a part of the study it was found that the probability of detecting stage 2, 3 or 4 fibrosis in a patient with NAFLD in combination with obesity is 5.5 times higher comparatively to patients with NAFLD without obesity (95% confidence interval: 3.0–11.3; p < 0.001). Also, in general regression analysis, it was determined that for liver fibrosis according to the results of indirect elastometry (IEM) in patients with diagnosed NAFLD, both with and without obesity, significant markers are the results of bioimpedansometry (fat mass in kg: β = 0.268, T = 4.08), biochemical parameters (gamma-glutamyltransferase level: β = 0.251, T = 4.01) and hormonal profile (visfatin level: β = 0.125, T = 2.05) at p < 0.05.
Conclusion. Adipose tissue mass, gamma-glutamyltransferase and visfatin levels may be the markers of increased probability of developing fibrosis in case of NAFLD.
Literature
1. Sveinbjornsson G., Ulfarsson M.O., Thorolfsdottir R.B. et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet. 2022; 54(11): 1652–63. https://doi.org/10.1038/s41588-022-01199-5. PMID: 36280732. PMCID: PMC9649432. 2. Jennison E., Byrne C.D. Recent advances in NAFLD: Current areas of contention. Faculty Reviews. 2023; 12: 10. https://doi.org/10.12703/r/12-10. PMID: 37153139. PMCID: PMC10155199. 3. Маевская М.В., Котовская Ю.В., Ивашкин В.Т. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022; 94(2): 216–253. (Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T. National consensus for physicians on the management of adult patients with nonalcoholic fatty liver disease and its major comorbid conditions. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(2): 216–253 (In Russ.)). https://doi.org/10.26442/00403660.2022.02.201363. EDN: CODINB. 4. Нелидова А.В., Ливзан М.А., Николаев Н.А. с соавт. Сердечно-сосудистые заболевания и неалкогольная жировая болезнь печени: связь и патогенетические аспекты фармакотерапии. Рациональная фармакотерапия в кардиологии. 2021; 17(6): 880–888. (Nelidova A.V., Livzan M.A., Nikolaev N.A. et al. Cardiovascular diseases and non-alcoholic fatty liver disease: connection and pathogenetic aspects of pharmacotherapy. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2021; 17(6): 880–888 (In Russ.)). https://doi.org/10.20996/1819-6446-2021-12-14. EDN: LVIINU. 5. Евстифеева С.Е., Шальнова С.А., Куценко В.А. с соавт. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022; 21(9): 40–49. (Evstifeeva S.E., Shalnova S.A., Kutsenko V.A. et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE-RF-2 data). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(9): 40–49 (In Russ.)). https://doi.org/10.15829/1728-8800-2022-3356. EDN: SITSBL. 6. Roderburg C., Krieg S., Krieg A. et al. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD). Eur J Med Res. 2023; 28(1): 153. https://doi.org/10.1186/s40001-023-01114-6. PMID: 37062837. PMCID: PMC10108448. 7. Younossi Z., Anstee Q.M., Marietti M. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018; 15(1): 11–20. https://doi.org/10.1038/nrgastro.2017.109. PMID: 28930295. 8. Uzlova N., Mnozil Stridova K., Merta D. et al. Transient elastography as the first-line assessment of liver fibrosis and its correlation with serum markers. Medicina (Kaunas). 2023; 59(4): 752. https://doi.org/10.3390/medicina59040752. PMID: 37109712. PMCID: PMC10146833. 9. Anstee Q.M., Castera L., Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol. 2022; 76(6): 1362–78. https://doi.org/10.1016/j.jhep.2022.03.026. PMID: 35589256. 10. Лазебник Л.Б., Голованова Е.В., Туркина С.В. с соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; (1): 4–52. (Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Non-alcoholic fatty liver disease in adults: Clinical picture, diagnosis, treatment. Recommendations for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; (1): 4–52 (In Russ.)). https://doi.org/10.31146/1682-8658-ecg-185-1-4-52. EDN: KJLOJV. 11. Драпкина О.М., Шепель Р.Н., Яковенко Э.П., Зятенкова Е.В. Неинвазивные методы выявления прогрессирующего фиброза у пациентов с неалкогольной жировой болезнью печени. Профилактическая медицина. 2019; 22(2): 82–88. (Drapkina O.M., Shepel R.N., Yakovenko E.P., Zyatenkova E.V. Non-invasive methods for detecting progressive fibrosis in patients with non-alcoholic fatty liver disease. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine. 2019; 22(2): 82–88 (In Russ.)). https://doi.org/10.17116/profmed20192202182. EDN: ZSZCLZ. 12. De Fre C.H., De Fre M.A., Kwanten W.J. et al. Sarcopenia in patients with non-alcoholic fatty liver disease: Is it a clinically significant entity? Obesity Reviews. 2019; 20(2): 353–63. https://doi.org/10.1111/obr.12776. PMID: 30474288. 13. Попова А.Ю., Тутельян В.А., Никитюк Д.Б. О новых (2021) Нормах физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации. Вопросы питания. 2021; 90(4): 6–19. (Popova A.Yu., Tutelyan V.A., Nikityuk D.B. About the new (2021) Standards of physiological needs for energy and nutrients for various groups of the population of the Russian Federation. Voprosy pitaniya = Nutrition Issues. 2021; 90(4): 6–19 (In Russ.)). https://doi.org/10.33029/0042-8833-2021-90-4-6-19. EDN: VSSZQJ. 14. Ахмедов В.А., Гаус О.В. Современные методы неинвазивной диагностики фиброза печени у больных неалкогольной жировой болезнью печени. Доктор.Ру. 2017; (2): 11–14. (Akhmedov V.A., Gaus O.V. Modern methods of non-invasive diagnosis of liver fibrosis in patients with non-alcoholic fatty liver disease Doctor.Ru. 2017; (2): 11–14 (In Russ.)). EDN: YLMUZH. 15. Sun J., Li Y., Sun X. et al. Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan. Exp Ther Med. 2019; 18(3): 1891–98. https://doi.org/10.3892/etm.2019.7727. PMID: 31410151. PMCID: PMC6676205. 16. Pattnaik K., Bhuyan P., Singh A. et al. Biopsy proven fibrosis in non-alcoholic fatty liver disease: An analysis of risk factors. J Clin Exp Hepatol. 2018; 8(4): 367–74. https://doi.org/10.1016/j.jceh.2017.12.008. PMID: 30563997. PMCID: PMC6286430. 17. Pouwels S., Sakran N., Graham Y. et al. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22(1): 63. https://doi.org/10.1186/s12902-022-00980-1. PMID: 35287643. PMCID: PMC8919523. 18. Younossi Z.M., Noureddin M., Bernstein D. et al. Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: Expert panel recommendations. Am J Gastroenterol. 2021; 116(2): 254–62. https://doi.org/10.14309/ajg.0000000000001054. PMID: 33284184. 19. Кручинина М.В., Курилович С.А., Громов А.А. с соавт. К вопросу о дифференциальной диагностике алкогольной и неалкогольной жировой болезни печени. Международный журнал прикладных и фундаментальных исследований. 2016; (7–1): 36–45. (Kruchinina M.V., Kurilovich S.A., Gromov A.A. et al. On the issue of differential diagnosis of alcoholic and non-alcoholic fatty liver disease. Mezhdunarodnyy zhurnal prikladnykh i fundamental’nykh issledovaniy = International Journal of Applied and Basic Research. 2016; (7–1): 36–45 (In Russ.)). EDN: WAPCRX. 20. Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS). Z Gastroenterol. 2022; 60(9): e733–e801. https://doi.org/10.1055/a-1880-2388. PMID: 36100201. 21. Ampuero J., Aller R., Gallego-Durán R. et al. HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018; 48(11–12): 1260–70. https://doi.org/10.1111/apt.15015. PMID: 30353552. 22. Hernandez-Conde M., Llop E., Carrillo C.F. et al. Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2020; 26(42): 6658–68. https://doi.org/10.3748/wjg.v26.i42.6658. PMID: 33268953. PMCID: PMC7673970. 23. Chen L.W., Huang M.S., Shyu Y.C., Chien R.N. Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study. Kaohsiung J Med Sci. 2021; 37(9): 819–27. https://doi.org/10.1002/kjm2.12395. Epub 2021 May 17. PMID: 34002481. 24. Kunutsor S.K. Gamma-glutamyltransferase – friend or foe within? Liver Int. 2016; 36(12): 1723–34. https://doi.org/10.1111/liv.13221. PMID: 27512925. 25. Kunutsor S.K., Apekey T.A., Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: A systematic review and dose-response meta-analysis. Int J Clin Pract. 2015, 69(1): 136–44. https://doi.org/10.1111/ijcp.12507. PMID: 25363194. 26. Sakugawa H., Nakayoshi T., Kobashigawa K. et al. Metabolic syndrome is directly associated with gamma glutamyl transpeptidase elevation in Japanese women. World J Gastroenterol. 2004; 10(7): 1052–55. https://doi.org/10.3748/wjg.v10.i7.1052. PMID: 15052692. PMCID: PMC4717098. 27. Ha Y., Chon Y.E., Kim M.N. et al. Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2022; 37(8): 1624–32. https://doi.org/10.1111/jgh.15871. PMID: 35467042. 28. Dakroub A., Nasser S.A., Younis N. et al. Visfatin: A possible role in cardiovasculo-metabolic disorders. Cells. 2020; 9(11): 2444. https://doi.org/10.3390/cells9112444. PMID: 33182523. PMCID: PMC7696687. 29. Francisco V., Sanz M.J., Real J.T. et al. Adipokines in non-alcoholic fatty liver disease: Are we on the road toward new biomarkers and therapeutic targets? Biology (Basel). 2022; 11(8): 1237. https://doi.org/10.3390/biology11081237. PMID: 36009862. PMCID: PMC9405285. 30. Carbone F., Liberale L., Bonaventura A. et al. Regulation and function of extracellular nicotinamide phosphoribosyltransferase/visfatin. Compr Physiol. 2017; 7(2): 603–21. https://doi.org/10.1002/cphy.c160029. PMID: 28333382. 31. Bekaert M., Verhelst X., Geerts A. et al. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: A systematic review. Obes Rev. 2016; 17(1): 68–80. https://doi.org/10.1111/obr.12333. PMID: 26597657. 32. Heo Y.J., Choi S.E., Lee N. et al. Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model. J Gastroenterol Hepatol. 2021; 36(9): 2592–600. https://doi.org/10.1111/jgh.15465. PMID: 33600604. 33. Ismaiel A., Leucuta D.C., Popa S.L., Dumitrascu D.L. Serum visfatin levels in nonalcoholic fatty liver disease and liver fibrosis: Systematic review and meta-analysis. J Clin Med. 2021; 10(14): 3029. https://doi.org/10.3390/jcm10143029. PMID: 34300193. PMCID: PMC8306785.
About the Autors
Elena A. Znakharenko, MD, postgraduate student of the Department of faculty therapy named after professor G.D. Zalessky, Novosibirsk State Medical University of the Ministry of Healthcare of Russia, nutritionist, gastroenterologist at Novosibirsk Regional Clinical Hospital of War Veterans No. 3. Address: 630091, Novosibirsk, 52 Krasny Avenue.
E-mail: znaxarenko85@bk.ru
ORCID: https://orcid.org/0000-0001-6408-6622
Oksana N. Gerasimenko, MD, Dr. Sci. (Medicine), professor, head of the Department of faculty therapy named after professor G.D. Zalessky of the Faculty of general medicine, Novosibirsk State Medical University of the Ministry of Healthcare of Russia, chief physician of Novosibirsk Regional Clinical Hospital of War Veterans No. 3, chief external expert in therapy and general medical practice of the Ministry of Healthcare of Novosibirsk region, Honored Doctor of the Russian Federation, Outstanding Worker of Healthcare of the Russian Federation. Address: 630091, Novosibirsk, 52 Krasny Avenue.
E-mail: profgerasimenko@inbox.ru
ORCID: https://orcid.org/0000-0002-9742-0479. SPIN-code: 7783-2977. AuthorID: 859018
Vladimir N. Maksimov, MD, Dr. Sci. (Medicine), professor, chief researcher, head of the Department of molecular genetic research work of therapeutic diseases, Research Institute of Therapy and Preventive Medicine – a branch of Institute of Cytology and Genetics of the Siberian branch of the Russian Academy of Sciences, professor of the Department of medical genetics and biology of the Faculty of general medicine, Novosibirsk State Medical University of the Ministry of Healthcare of Russia. Address: 630091, Novosibirsk, 52 Krasny Avenue.
E-mail: medik11@mail.ru
ORCID: https://orcid.org/0000-0002-7165-4496. SPIN-code: 9953-7867. AuthorID: 122965
Alena M. Gorbunova, MD, postgraduate student, assistant, head of the educational unit of the Department of faculty therapy named after Professor G.D. Zalessky, Novosibirsk State Medical University of the Ministry of Healthcare of Russia, general practitioner, geriatrician at Novosibirsk Regional Clinical Hospital of War Veterans No. 3. Address: 630091, Novosibirsk, 52 Krasny Avenue.
E-mail: belyaeva-alena@list.ru
ORCID: https://orcid.org/0000-0002-1593-3984
Similar Articles
